The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Irritable Bowel Syndrome Treatment Drug Market Research Report 2024
Synopsis
Irritable bowel syndrome (IBS) is a common condition that affects the digestive system. It causes symptoms like stomach cramps, bloating, diarrhoea and constipation. These tend to come and go over time, and can last for days, weeks or months at a time. It's usually a lifelong problem.
Global Irritable Bowel Syndrome Treatment Drug market is projected to reach US$ 4348.9 million in 2029, increasing from US$ 3515 million in 2022, with the CAGR of 3.1% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Irritable Bowel Syndrome Treatment Drug market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Irritable Bowel Syndrome Treatment Drug market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Abbvie Inc.
Bristol Myers Squibb
Roche
Johnson & Johnson
Pfizer Inc.
Prometheus Laboratories Inc. (Nestle)
Bausch Health
Takeda Pharmaceutical Ltd
Biogen
AstraZeneca
Segment by Type
Antibiotics
Amino Salicylates
Corticosteroids
Immunomodulators
Others
Segment by Application
Hospitals
Specialty Clinics
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Irritable Bowel Syndrome Treatment Drug report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies' Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Irritable bowel syndrome (IBS) is a common condition that affects the digestive system. It causes symptoms like stomach cramps, bloating, diarrhoea and constipation. These tend to come and go over time, and can last for days, weeks or months at a time. It's usually a lifelong problem.
Global Irritable Bowel Syndrome Treatment Drug market is projected to reach US$ 4348.9 million in 2029, increasing from US$ 3515 million in 2022, with the CAGR of 3.1% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Irritable Bowel Syndrome Treatment Drug market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Irritable Bowel Syndrome Treatment Drug market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Abbvie Inc.
Bristol Myers Squibb
Roche
Johnson & Johnson
Pfizer Inc.
Prometheus Laboratories Inc. (Nestle)
Bausch Health
Takeda Pharmaceutical Ltd
Biogen
AstraZeneca
Segment by Type
Antibiotics
Amino Salicylates
Corticosteroids
Immunomodulators
Others
Segment by Application
Hospitals
Specialty Clinics
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Irritable Bowel Syndrome Treatment Drug report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies' Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Irritable Bowel Syndrome Treatment Drug Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Antibiotics
1.2.3 Amino Salicylates
1.2.4 Corticosteroids
1.2.5 Immunomodulators
1.2.6 Others
1.3 Market by Application
1.3.1 Global Irritable Bowel Syndrome Treatment Drug Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospitals
1.3.3 Specialty Clinics
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Irritable Bowel Syndrome Treatment Drug Market Perspective (2018-2029)
2.2 Irritable Bowel Syndrome Treatment Drug Growth Trends by Region
2.2.1 Global Irritable Bowel Syndrome Treatment Drug Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Irritable Bowel Syndrome Treatment Drug Historic Market Size by Region (2018-2023)
2.2.3 Irritable Bowel Syndrome Treatment Drug Forecasted Market Size by Region (2024-2029)
2.3 Irritable Bowel Syndrome Treatment Drug Market Dynamics
2.3.1 Irritable Bowel Syndrome Treatment Drug Industry Trends
2.3.2 Irritable Bowel Syndrome Treatment Drug Market Drivers
2.3.3 Irritable Bowel Syndrome Treatment Drug Market Challenges
2.3.4 Irritable Bowel Syndrome Treatment Drug Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Irritable Bowel Syndrome Treatment Drug Players by Revenue
3.1.1 Global Top Irritable Bowel Syndrome Treatment Drug Players by Revenue (2018-2023)
3.1.2 Global Irritable Bowel Syndrome Treatment Drug Revenue Market Share by Players (2018-2023)
3.2 Global Irritable Bowel Syndrome Treatment Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Irritable Bowel Syndrome Treatment Drug Revenue
3.4 Global Irritable Bowel Syndrome Treatment Drug Market Concentration Ratio
3.4.1 Global Irritable Bowel Syndrome Treatment Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Irritable Bowel Syndrome Treatment Drug Revenue in 2022
3.5 Irritable Bowel Syndrome Treatment Drug Key Players Head office and Area Served
3.6 Key Players Irritable Bowel Syndrome Treatment Drug Product Solution and Service
3.7 Date of Enter into Irritable Bowel Syndrome Treatment Drug Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Irritable Bowel Syndrome Treatment Drug Breakdown Data by Type
4.1 Global Irritable Bowel Syndrome Treatment Drug Historic Market Size by Type (2018-2023)
4.2 Global Irritable Bowel Syndrome Treatment Drug Forecasted Market Size by Type (2024-2029)
5 Irritable Bowel Syndrome Treatment Drug Breakdown Data by Application
5.1 Global Irritable Bowel Syndrome Treatment Drug Historic Market Size by Application (2018-2023)
5.2 Global Irritable Bowel Syndrome Treatment Drug Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Irritable Bowel Syndrome Treatment Drug Market Size (2018-2029)
6.2 North America Irritable Bowel Syndrome Treatment Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Irritable Bowel Syndrome Treatment Drug Market Size by Country (2018-2023)
6.4 North America Irritable Bowel Syndrome Treatment Drug Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Irritable Bowel Syndrome Treatment Drug Market Size (2018-2029)
7.2 Europe Irritable Bowel Syndrome Treatment Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Irritable Bowel Syndrome Treatment Drug Market Size by Country (2018-2023)
7.4 Europe Irritable Bowel Syndrome Treatment Drug Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Irritable Bowel Syndrome Treatment Drug Market Size (2018-2029)
8.2 Asia-Pacific Irritable Bowel Syndrome Treatment Drug Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Irritable Bowel Syndrome Treatment Drug Market Size by Region (2018-2023)
8.4 Asia-Pacific Irritable Bowel Syndrome Treatment Drug Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Irritable Bowel Syndrome Treatment Drug Market Size (2018-2029)
9.2 Latin America Irritable Bowel Syndrome Treatment Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Irritable Bowel Syndrome Treatment Drug Market Size by Country (2018-2023)
9.4 Latin America Irritable Bowel Syndrome Treatment Drug Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Irritable Bowel Syndrome Treatment Drug Market Size (2018-2029)
10.2 Middle East & Africa Irritable Bowel Syndrome Treatment Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Irritable Bowel Syndrome Treatment Drug Market Size by Country (2018-2023)
10.4 Middle East & Africa Irritable Bowel Syndrome Treatment Drug Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Abbvie Inc.
11.1.1 Abbvie Inc. Company Detail
11.1.2 Abbvie Inc. Business Overview
11.1.3 Abbvie Inc. Irritable Bowel Syndrome Treatment Drug Introduction
11.1.4 Abbvie Inc. Revenue in Irritable Bowel Syndrome Treatment Drug Business (2018-2023)
11.1.5 Abbvie Inc. Recent Development
11.2 Bristol Myers Squibb
11.2.1 Bristol Myers Squibb Company Detail
11.2.2 Bristol Myers Squibb Business Overview
11.2.3 Bristol Myers Squibb Irritable Bowel Syndrome Treatment Drug Introduction
11.2.4 Bristol Myers Squibb Revenue in Irritable Bowel Syndrome Treatment Drug Business (2018-2023)
11.2.5 Bristol Myers Squibb Recent Development
11.3 Roche
11.3.1 Roche Company Detail
11.3.2 Roche Business Overview
11.3.3 Roche Irritable Bowel Syndrome Treatment Drug Introduction
11.3.4 Roche Revenue in Irritable Bowel Syndrome Treatment Drug Business (2018-2023)
11.3.5 Roche Recent Development
11.4 Johnson & Johnson
11.4.1 Johnson & Johnson Company Detail
11.4.2 Johnson & Johnson Business Overview
11.4.3 Johnson & Johnson Irritable Bowel Syndrome Treatment Drug Introduction
11.4.4 Johnson & Johnson Revenue in Irritable Bowel Syndrome Treatment Drug Business (2018-2023)
11.4.5 Johnson & Johnson Recent Development
11.5 Pfizer Inc.
11.5.1 Pfizer Inc. Company Detail
11.5.2 Pfizer Inc. Business Overview
11.5.3 Pfizer Inc. Irritable Bowel Syndrome Treatment Drug Introduction
11.5.4 Pfizer Inc. Revenue in Irritable Bowel Syndrome Treatment Drug Business (2018-2023)
11.5.5 Pfizer Inc. Recent Development
11.6 Prometheus Laboratories Inc. (Nestle)
11.6.1 Prometheus Laboratories Inc. (Nestle) Company Detail
11.6.2 Prometheus Laboratories Inc. (Nestle) Business Overview
11.6.3 Prometheus Laboratories Inc. (Nestle) Irritable Bowel Syndrome Treatment Drug Introduction
11.6.4 Prometheus Laboratories Inc. (Nestle) Revenue in Irritable Bowel Syndrome Treatment Drug Business (2018-2023)
11.6.5 Prometheus Laboratories Inc. (Nestle) Recent Development
11.7 Bausch Health
11.7.1 Bausch Health Company Detail
11.7.2 Bausch Health Business Overview
11.7.3 Bausch Health Irritable Bowel Syndrome Treatment Drug Introduction
11.7.4 Bausch Health Revenue in Irritable Bowel Syndrome Treatment Drug Business (2018-2023)
11.7.5 Bausch Health Recent Development
11.8 Takeda Pharmaceutical Ltd
11.8.1 Takeda Pharmaceutical Ltd Company Detail
11.8.2 Takeda Pharmaceutical Ltd Business Overview
11.8.3 Takeda Pharmaceutical Ltd Irritable Bowel Syndrome Treatment Drug Introduction
11.8.4 Takeda Pharmaceutical Ltd Revenue in Irritable Bowel Syndrome Treatment Drug Business (2018-2023)
11.8.5 Takeda Pharmaceutical Ltd Recent Development
11.9 Biogen
11.9.1 Biogen Company Detail
11.9.2 Biogen Business Overview
11.9.3 Biogen Irritable Bowel Syndrome Treatment Drug Introduction
11.9.4 Biogen Revenue in Irritable Bowel Syndrome Treatment Drug Business (2018-2023)
11.9.5 Biogen Recent Development
11.10 AstraZeneca
11.10.1 AstraZeneca Company Detail
11.10.2 AstraZeneca Business Overview
11.10.3 AstraZeneca Irritable Bowel Syndrome Treatment Drug Introduction
11.10.4 AstraZeneca Revenue in Irritable Bowel Syndrome Treatment Drug Business (2018-2023)
11.10.5 AstraZeneca Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
